Quantified Tumor T1 Is a Generic Early-Response Imaging Biomarker for Chemotherapy Reflecting Cell Viability
Open Access
- 1 January 2010
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (1) , 212-225
Abstract
Purpose: Identification of a generic response biomarker by comparison of chemotherapeutics with different action mechanisms on several noninvasive biomarkers in experimental tumor models.Keywords
All Related Versions
This publication has 43 references indexed in Scilit:
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic DataJournal of Clinical Oncology, 2008
- Distinct Role of Macrophages in Different Tumor MicroenvironmentsCancer Research, 2006
- Monitoring fluoropyrimidine metabolism in solid tumors with in vivo 19F magnetic resonance spectroscopyCritical Reviews in Oncology/Hematology, 2005
- Clinical trials in ovarian carcinoma: study methodologyAnnals of Oncology, 2005
- Measurements of T1 and T2 relaxation times of colon cancer metastases in rat liver at 7 TMagnetic Resonance Materials in Physics, Biology and Medicine, 2004
- A review of structural magnetic resonance neuroimagingJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Magnetic Resonance Imaging of Human Melanoma Xenograftsin Vivo: Proton Spin—lattice and Spin—spin Relaxation Times Versus Fractional Tumour Water Content and Fraction of Necrotic Tumour TissueInternational Journal of Radiation Biology, 1994
- Quantitative magnetic resonance imaging in cervical carcinoma: a report on 30 casesBritish Journal of Radiology, 1991
- Continuous distributions of NMR relaxation times applied to tumors before and after therapy with X‐rays and cyclophosphamideMagnetic Resonance in Medicine, 1988